Drug
Duloxetine
Duloxetine: highest development phase Approved, developed by Eli Lilly, Shionogi, Teva. 8 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- Eli Lilly, Shionogi, Teva
Trials
| Drug | Phase | Indication |
|---|---|---|
| DULOXETINE HYDROCHLORIDE | Approved | |
| CYMBALTA | Approved | |
| Duloxetine NCT01855919 | Phase 3 | Back Pain Lower Back Chronic |
| Duloxetine Hydrochloride NCT00191919 | Phase 3 | Depressive Disorder, Major |
| Duloxetine NCT01621191 | Phase 3 | Fibromyalgia |
| Duloxetine NCT02248480 | Phase 3 | Osteoarthritis of the Knee |
| Duloxetine Hydrochloride NCT03395353 | Phase 3 | Depressive Disorder |
| Duloxetine NCT00475696 | Phase 2 | Urinary Incontinence |
Latest
No recent events.
Follow Duloxetine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.